Literature DB >> 18586111

Safety and secondary pharmacology: successes, threats, challenges and opportunities.

Jean-Pierre Valentin1, Tim Hammond.   

Abstract

This review summarises the lecture of Dr Tim Hammond, recipient of the Distinguished Service Award of the Safety Pharmacology Society, given on 20 September 2007 in Edinburgh. The lecture discussed the rationale behind the need for optimal non-clinical Safety and Secondary Pharmacology testing; the evolution of Safety and Secondary Pharmacology over the last decade; its impact on drug discovery and development; the value of adopting an integrated risk assessment approach; the translation of non-clinical findings to humans and finally the future challenges and opportunities facing these disciplines.

Entities:  

Mesh：

Year:  2008        PMID： 18586111     DOI： 10.1016/j.vascn.2008.05.007

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN： 1056-8719            Impact factor:   1.950


  15 in total

Review 1.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

Review 2.  Assays for the identification and prioritization of drug candidates for spinal muscular atrophy.

Authors:  Jonathan J Cherry; Dione T Kobayashi; Maureen M Lynes; Nikolai N Naryshkin; Francesco Danilo Tiziano; Phillip G Zaworski; Lee L Rubin; Jill Jarecki
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

3.  On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex.

Authors:  A R Harmer; J-P Valentin; C E Pollard
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

4.  hERG subunit composition determines differential drug sensitivity.

Authors:  N Abi-Gerges; H Holkham; E M C Jones; C E Pollard; J-P Valentin; G A Robertson
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 5.  Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.

Authors:  Jean-Pierre Valentin; Chris Pollard; Pierre Lainée; Tim Hammond
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

6.  Cardiac microphysiological devices with flexible thin-film sensors for higher-throughput drug screening.

Authors:  Johan U Lind; Moran Yadid; Ian Perkins; Blakely B O'Connor; Feyisayo Eweje; Christophe O Chantre; Matthew A Hemphill; Hongyan Yuan; Patrick H Campbell; Joost J Vlassak; Kevin K Parker
Journal:  Lab Chip       Date:  2017-10-25       Impact factor: 6.799

7.  Increased Late Sodium Current Contributes to the Electrophysiological Effects of Chronic, but Not Acute, Dofetilide Administration.

Authors:  Xiaoliang S Qiu; Samuel Chauveau; Evgeny P Anyukhovsky; Tania Rahim; Ya-Ping Jiang; Erin Harleton; Steven J Feinmark; Richard Z Lin; Ruben Coronel; Michiel J Janse; Tobias Opthof; Tove S Rosen; Ira S Cohen; Michael R Rosen
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-04

8.  Cassia auriculata: Aspects of Safety Pharmacology and Drug Interaction.

Authors:  Amrutesh S Puranik; Ganesh Halade; Sandeep Kumar; Ranjan Mogre; Kishori Apte; Ashok D B Vaidya; Bhushan Patwardhan
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-03       Impact factor: 2.629

9.  Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.

Authors:  Gary R Mirams; Yi Cui; Anna Sher; Martin Fink; Jonathan Cooper; Bronagh M Heath; Nick C McMahon; David J Gavaghan; Denis Noble
Journal:  Cardiovasc Res       Date:  2011-02-07       Impact factor: 10.787

10.  Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials.

Authors:  Nejib Zemzemi; Miguel O Bernabeu; Javier Saiz; Jonathan Cooper; Pras Pathmanathan; Gary R Mirams; Joe Pitt-Francis; Blanca Rodriguez
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.